



April 11, 2022

## ASX ANNOUNCEMENT

### Control Bionics Enters Japanese Market with NeuroNode Technology

**Control Bionics Limited (ASX: CBL) to launch its technology in Japan in partnership with major assistive technology distributor, Double R&D Co Ltd (“Double R&D”).**

Control Bionics has entered into an agreement with Double R&D to introduce its NeuroNode Trilogy technology to people with conditions like ALS, cerebral palsy, intellectual disability, stroke and traumatic brain injuries. The CBL initiative will be led by our Japanese executive, Erica Kitayama.

**Control Bionics’ technology will be introduced to Japan at KidsFesta in Tokyo on the 16<sup>th</sup> and 17<sup>th</sup> of April 2022, Japan’s largest disability event focussed on children.\***

Double R&D President Hiroshi Wada said “We feel honoured and excited about this opportunity to distribute NeuroNode Trilogy which is innovative and world leading AAC product in Japan. It remains vividly in my memory of the first experience of NeuroNode Trilogy a year ago. We are confident that the users of NeuroNode will experiences their new life and we will bring smile to patients, their family, caretakers and all of their supporters in Japan. We would like Control Bionics to look forward to our success in Japan.”

CBL CEO Rob Wong said: “We are extremely honoured to be partnering with Double R&D after working diligently with them to localise our NeuroNode Trilogy and software for the Japanese market. We believe there is a significant need for our technology across Japan.”

The CBL flagship NeuroNode Trilogy system allows non-verbal people with severely impaired movement to control a computer for speech generation, gaming, email and text, with ease and speed. NeuroNode Trilogy is up to 47% faster than traditional eye-gaze systems with significantly less user fatigue.

The initial focus of the CBL/Double R&D partnership will be to train over 30 resellers on the life-changing technology within Double R&D’s network.

#### About Double R&D

Double R&D is a leading-edge industrial robot and factory automation equipment manufacturer with a 45-year history. They have distributed AAC equipment to patients with

For personal use only



intractable neurological diseases in Japan for over 24 years. They are proud of the successful 3,000 AAC installation experiences with their expertise and trust in Japan market. Double R&D is centrally located within a one hour train ride from major population centres of Tokyo, Yokohama and Kawasaki.

### **Double R&D agreement**

The material terms of the Double R&D agreement are as follows:

1. The distributor is Double R&D.
2. The agreement appoints Double R&D as the exclusive distributor in Japan of Trilogy products and any other CBL products which CBL and Double R&D subsequently agree (collectively referred to as the **Products**).
3. Double R&D shall order products from CBL based on the price list included in the agreement. CBL may amend the pricing upon giving 30 days written notice to Double R&D.
4. The term of agreement is continuous and shall terminate upon the terms of the agreement. Either party may terminate the agreement without cause by giving six months prior written notice, such termination to occur at any date after the second anniversary of the commencement of the agreement. The agreement has standard termination provisions found in commercial agreements of this kind in relation to default as a result of insolvency or breach of the agreement which is not remedied.
5. The agreement has no provision for minimum order purchase quantities, other than a requirement for Double R&D to use best efforts to meet an agreed sales forecast.
6. The agreement has no conditions precedent.

This announcement was authorised by CBL CEO, Rob Wong.

For more information, contact:

Erica Kitayama  
Country Representative  
Tokyo  
[erica@controlbionics.com](mailto:erica@controlbionics.com)

Rob Wong  
CEO  
Control Bionics Limited  
[robwong@controlbionics.com](mailto:robwong@controlbionics.com)

For personal use only

# CONTROL BIONICS

## About Control Bionics:

Control Bionics is a technology company which enables a disabled person to use their own neuroelectric signals, from their brain to a muscle, to control communication and movement through smartphones, tablets, computers and robotics, even when that muscle is not fully functional. The Company's wearable, wireless device, 'NeuroNode', is a world leader in electromyography (EMG), capturing and processing those neuroelectric signals into electronic commands to do everything they would normally do with a keyboard, mouse, joystick or touchscreen. The NeuroNode Trilogy when combined with other access methods such as eye-gaze, enables a person to use their eyes to replace a mouse in controlling a cursor on a screen simply by looking where they want to cursor to move; and then to select anything under the cursor, using NeuroNode; providing fast, intuitive communication and control through text, text-to-speech, emails, phone-messaging, web surfing and robotics."

[Video Of NeuroNode Trilogy Working for a client](#)



\*KidsFesta is the largest disability event for children in Japan, with a 20 year history (21<sup>st</sup> event in 2022). The event is expected to attract over 10,000 visitors even in the current Covid-19 environment.